Young men are being encouraged to undergo testosterone testing and start hormone therapy through Instagram and TikTok content that promotes unproven health claims while downplaying medical risks, a ...
Halozyme (HALO) outlook: acquisitions extend IP beyond 2027, royalties are set to top $1B in 2026, and shares look discounted ...
Influencers issue warnings that “low T is ruining young men.” Recently, the Department of Health and Human Services has gone all in on the hormone, publishing new dietary guidelines meant to help men ...
Subcutaneous Saphnelo may offer people with lupus more convenient dosing with efficacy similar to the approved infusion version of the therapy, data show.
Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
8don MSN
Considering testosterone therapy? We break down the entire process from diagnosis to monitoring
Learn how testosterone therapy works step by step, including diagnosis, treatment options, monitoring, and potential risks ...
PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical ...
A Food and Drug Administration panel of health experts convened Wednesday to discuss and promote the health benefits of testosterone treatments for men. FDA Commissioner Martin Makary told Morning ...
This is T-rrific news for some men. Testosterone replacement therapy (TRT) has been historically difficult to get because it requires proof of consistently low testosterone levels along with symptoms ...
Temporarily shutting down a "lazy eye" triggers a burst of neuronal activity that reverses the condition in animal experiments, a study shows. When you purchase through links on our site, we may earn ...
Annalisa (Nalis) Merelli is a contributing writer at STAT focused on boys’ and men’s health. Increased physical stamina. “Facility of intellectual labour.” A longer jet of urine. These were some of ...
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results